Entity

Time filter

Source Type

San Diego, CA, United States

Mao H.,Fabrus LLC | Graziano J.J.,Fabrus LLC | Chase T.M.A.,Fabrus LLC | Bentley C.A.,Fabrus LLC | And 6 more authors.
Nature Biotechnology | Year: 2010

Antibody discovery typically uses hybridoma- or display-based selection approaches, which lack the advantages of directly screening spatially addressed compound libraries as in small-molecule discovery. Here we apply the latter strategy to antibody discovery, using a library of ĝ̂1/410,000 human germline antibody Fabs created by de novo DNA synthesis and automated protein expression and purification. In multiplexed screening assays, we obtained specific hits against seven of nine antigens. Using sequence-activity relationships and iterative mutagenesis, we optimized the binding affinities of two hits to the low nanomolar range. The matured Fabs showed full and partial antagonism activities in cell-based assays. Thus, protein drug leads can be discovered using surprisingly small libraries of proteins with known sequences, questioning the requirement for billions of members in an antibody discovery library. This methodology also provides sequence, expression and specificity information at the first step of the discovery process, and could enable novel antibody discovery in functional screens. © 2010 Nature America, Inc. All rights reserved. Source

Discover hidden collaborations